Challenges in stem cell-derived islet replacement therapy can be overcome

Midhat H. Abdulreda, Per-Olof Berggren

Research output: Contribution to journalArticlepeer-review

12 Downloads (Pure)

Abstract

In this Commentary, we echo the conclusions of a recent review titled “The promise of stem cell-derived islet replacement therapy,” which highlighted recent advances in producing glucose responsive “islets” from stem cells and the benefits of their use in islet transplant therapy in type 1 diabetes (T1D). The review also outlined the status of clinical islet transplantation and the challenges that have prevented it from reaching its full therapeutic promise. We agree with the conclusions of the review and suggest that the identified challenges may be overcome by using the eye anterior chamber as an islet transplant site. We anticipate that the combination of stem cell-derived islets and intraocular transplant could help this promising T1D therapy reach full fruition.
Original languageEnglish
Pages (from-to)1-5
JournalCell Transplantation
Volume30
DOIs
Publication statusPublished - 27 Sep 2021

Bibliographical note

Funding Information:
The authors would like to acknowledge colleagues on prior works that supported the opinions expressed in this commentary. The authors also acknowledge the help of Zein M. Abdulreda and Tilo Moede in creating the scheme shown in Fig. 1. The author(s) disclosed receipt of the following financial support for the research referenced in this article: Our work was supported in part through funds from the Diabetes Research Institute Foundation (DRIF) and the Diabetes Wellness Foundation and through grants from the National Institute of Allergy and Infectious Diseases (NIAID)?? R56AI130330?? the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)?? F32DK083226 and K01DK097194. It was also supported in part by the Swedish Research Council, the Family Erling-Persson Foundation, the Novo Nordisk Foundation, the Stichting af Jochnick Foundation, the Swedish Diabetes Association, the Berth von Kantzow?s Foundation, the Strategic Research Program in Diabetes at Karolinska Institutet, the European Research Council grant ERC-2018-AdG834860EYELETS, the Swedish Foundation for Strategic Research, and the Knut and Alice Wallenberg Foundation.

Funding Information:
The author(s) disclosed receipt of the following financial support for the research referenced in this article: Our work was supported in part through funds from the Diabetes Research Institute Foundation (DRIF) and the Diabetes Wellness Foundation and through grants from the National Institute of Allergy and Infectious Diseases (NIAID) – R56AI130330 – the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) – F32DK083226 and K01DK097194. It was also supported in part by the Swedish Research Council, the Family Erling-Persson Foundation, the Novo Nordisk Foundation, the Stichting af Jochnick Foundation, the Swedish Diabetes Association, the Berth von Kantzow’s Foundation, the Strategic Research Program in Diabetes at Karolinska Institutet, the European Research Council grant ERC-2018-AdG834860EYELETS, the Swedish Foundation for Strategic Research, and the Knut and Alice Wallenberg Foundation.

Publisher Copyright:
© The Author(s) 2021.

Keywords

  • stem cell-derived islets, glucose responsive, insulin insufficiency, insulin independence, diabetes, anterior chamber of the eye, intraocular transplantation, islet transplant, immune rejection, immune tolerance
  • glucose responsive
  • insulin insufficiency
  • insulin independence
  • diabetes
  • anterior chamber of the eye,
  • intraocular transplantation,
  • islet transplant
  • immune rejection
  • immune tolerance

Fingerprint

Dive into the research topics of 'Challenges in stem cell-derived islet replacement therapy can be overcome'. Together they form a unique fingerprint.

Cite this